The Psychedelic category covers everything from basic explanations of psychoactive substances such as psilocybin, MDMA, ketamine, DMT, and ahyahuasca, to weekly news, the latest discussions in psychiatry, regulatory trends, and research and development developments. This collection of information is for readers who want to understand how therapeutic applications, risk assessment, social acceptance, and institutional design are progressing within the international trend known as the Psychedelic Renaissance. This category is suitable for those who want to understand psychedelia from a perspective that spans medicine, culture, policy, and a substance dictionary, and for those who want to follow overseas research and practical regulatory information simultaneously. It is suitable for readers who want to get an overview of the psychedelic field, as it allows them to check clinical research, regulatory discussions, and a basic understanding of each substance from a single entry point.
We've organized the psychedelic category updates chronologically, and made it possible to see links to related guides on the same screen as needed.
This Week's Psychedelic Articles Overview: In the United States, while federal-level scheduling continues, progress is being made in the institutional design and financial aspects of state programs. Attention is also being drawn to "training" and "standardization" to bridge the gap between clinical practice and real-world application, and research funding and public-private partnerships are expanding. Research & Academia California...
This week's psychedelic news overview: There has been a series of developments in US regulations and policy. At the federal level, the DEA is attempting to again grant Schedule I designation to five tryptamines, and the FDA is holding public hearings on the future use of psychedelics. At the state level, Oregon is reviewing its policy of raising fees related to psilocybin...
This Week's Psychedelic News Overview: This week saw the publication of a peer-reviewed paper measuring the impact of decriminalization from the perspective of those directly affected, and at the US federal level, ARPA-H moved to concretize its support for ibogaine. On the corporate front, Compass Pathways shared progress on its Phase 3 trial, and new players entered clinical trials. In the media,...
This Week's Psychedelic News Overview: This week's major topics included the US FDA's public hearing on psychedelic drugs and the presentation of a "new framework" by FDA officials in the NEJM (New England Journal of Medicine). In research and clinical practice, there were company announcements of continued positive results in Phase 3 trials of LSD-based drug candidates, and...
To help you supplement your understanding of the news as you read, we've compiled a summary of the systems, terminology, and introductory points here.
This is an entry point to a guide that organizes information on system changes and how to interpret government announcements.
This can be used as a place to refer to ingredient names or technical terms when they come up.
This is an entry point for those who want to transition directly from the news list into the learning process.
This Week's Psychedelic News Overview: This week saw notable developments in the "clinical implementation" and "regulation" of psychedelic medicine. While progress was made in the practical application of MDMA prescriptions in New Zealand, debate surrounding the DEA's emergency designation reignited in the US. Interest in safety management (REMS) in anticipation of US FDA approval also increased. Investment...
This Week's Psychedelic Articles Overview: This week saw a noticeable increase in search advertising activity from pharmaceutical companies. In clinical development, a follow-up report delving into the Phase 3 results of LSD-based anxiety treatment emerged. In education and awareness, proposals were presented to reconsider traditional "psychedelic" presentation methods. Specific institutional updates are detailed within the material...
This Week's Psychedelic News Overview: This week saw progress in regulation and review alongside discussions on access in the field. In addition to the resubmission of applications for MDMA treatment, the results of Phase 3 LSD trials, and the establishment of systems within US federal agencies, issues of program operation and funding at the state level also emerged. On the research infrastructure side, open science progress was made in ibogaine data, and major research projects on cannabis and the brain...
This Week's Psychedelic News Overview: In the US, the FDA finalized its clinical trial guidance for psychedelic adjunctive therapy and announced schedules for public hearings and public comment periods. The federal agency VA launched a multicenter trial of psilocybin for veteran patients with treatment-resistant depression. On the corporate side, AI-powered clinical trial support is progressing, with a prospective Phase 3 trial of LSD...
This Week's Psychedelic Articles (Week 2, August 2026) Overview: In the US, federal and state-level developments are accelerating in parallel. The Department of Veterans Affairs (VA) has begun a multi-center trial of psilocybin, and Congress is making progress in expanding research through the National Defense Authorization Act (NDAA). A New Drug Application (NDA) for MDMA-supported therapy has been resubmitted to the FDA, and regulatory guidelines are being issued...
This Week's Psychedelic News Overview: In the United States, a series of federal policies were implemented, including amendments to the National Defense Authorization Act (FY2027) and the extension of Department of Defense programs. The Department of Veterans Affairs (VA) released the number of ongoing trials, and Louisiana began using opioid settlement funds for psychedelic research. Both regulatory and financial aspects are being addressed…
This Week's Psychedelic Articles Overview: This week saw a series of articles re-examining the "for whom" model of research and clinical implementation, while simultaneously accelerating institutional and market changes, including updated service operation data from Oregon, records of massive fundraising, and movements by megapharmaceutical companies. Research, regulation, and business intersected, leading to model transformation and industrialization...
This Week's Psychedelic News Overview: This week saw the announcement of a major acquisition by a pharmaceutical giant, and a series of policy developments related to expanding access in the Americas and Canada. The latest development updates were also released, making it a week filled with news in research, regulation, and business. Research & Development: Psychedelic Alp...
This Week's Psychedelics News Overview: In the US, federal agencies are accelerating their efforts. The FDA has finalized its guidance for psychedelic clinical trials and announced a hearing in September. In terms of research, Harvard is advancing its ibogaine addiction research with approximately $11 million in funding from the NIDA. In Europe, France is also working on psilocybin II...
This Week's Psychedelic News Overview: This week, Compass Pathways released 26-week (approximately 6-month) data from its Phase 3 Second Trial of COMP360 (psilocybin) for treatment-resistant depression (TRD). In the US, there have been proposals for ibogaine-related legislation, a proposed increase in psilocybin facility fees in Oregon, and the DEA...
This Week's Psychedelic News Overview: This week saw simultaneous progress in "foundation building" and "implementation" across research, regulation, and industry. MAPS opened up research and regulatory documents on ibogaine, and parliamentary-led dialogue progressed in Europe. In the US, state-level regulatory design advanced, and companies announced Phase 3 trials for LSD as an antidepressant...
This Week's Psychedelic Articles (Week of June 22, 2026) Overview: In the US, preparations for expanded access and stricter enforcement are progressing simultaneously at the federal level, while at the state level, legislation and budgets related to ibogaine and psilocybin are moving forward. In the judiciary, the Supreme Court ruled to narrowly interpret the blanket ban on gun ownership for drug users. Research...
This week's psychedelic news overview: In Europe, Germany quietly launches the EU's first psilocybin "compassionate use" framework. In the Czech Republic, debate is intensifying over a change in jurisdiction regarding its long-standing integrated drug policy. In the US, several states are seeing a series of institutional changes, including improvements to research funding and convenience...
This Week's Psychedelic Articles Overview: The US state legislature season has passed its peak, with 17 of the 115 related bills tracked this year having been passed. While over a quarter of the bills passed were concentrated in May alone, two were vetoed and 44 expired at the end of the session. Although policy-making activity has slowed, the implementation phase of institutional design remains...
This Week's Psychedelic Articles Overview: This week saw a combination of events: a report from the American Psychiatric Association (APA) annual meeting, news surrounding FDA personnel and review trends, and the announcement of a new project by MAPS focusing on the intersection of criminal justice and mental health. In the research, regulatory, and business spheres, there was a focus on "re-evaluating positioning" and "application..."
This week's Psychedelic article summary: At the US Federal Summit, practical challenges for implementation (REMS, rescheduling, ARPA-H's EVIDENT plan, and informed consent ethics) were discussed intensively. Reference: Psychedelic Alpha discusses the new format "Fi...
